Cardiac Amyloidosis (CA) is a condition where abnormal proteins build up in the heart, causing heart failure with a preserved left ventricular ejection fraction, also known as HFpEF. In simpler terms, the heart struggles to pump blood effectively despite the heart muscle appearing normal. This study focuses on Tunisian patients with HFpEF to see how common CA is and find ways to predict it using clinical checks and ultrasound. Diagnosing CA early can help improve patient outcomes. There are two main types of CA: TTR and AL, and identifying them early is crucial. To participate in this study, patients must have had HFpEF in the past year and a heart wall thickness (IVS) of 12mm or more. The study excludes those under 60, patients with recent heart attacks leading to HFpEF, or congenital (from birth) heart issues.

• Participants must be 60 years or older.
• Study focuses on heart ultrasound and clinical assessments.
• No congenital heart disease or recent heart attack patients allowed.